Because SARS-CoV-2 shares similar genomic sequences with SARS-CoV and MERS-CoV, CP therapy can be considered a promising treatment strategy with the potential to help the infected patients develop immediate short-term passive immunization before the availability of a new generation of COVID-19 vaccines. Here, CP is linked to COVID-19.